-
Founded in:
2008-06-26 -
Country:
China -
Address:
No. 1503, Meishan Road, Economic and Technological Development Zone, Ma'anshan City, Anhui Province -
Tax NO.:
913405006758985090 -
Registered Funds:
145.5 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Choline cytosine diphosphate monosodium salt |
It promotes brain metabolism and improves brain circulation by reducing cerebrovascular resistance and increasing cerebral blood flow. It also enhances the function of the ascending activation system of the brainstem reticular structure, the function of the pyramidal system, improves motor paralysis, and has a certain effect on promoting the recovery of brain function and awakening.
More
It promotes brain metabolism and improves brain circulation by reducing cerebrovascular resistance and increasing cerebral blood flow. It also enhances the function of the ascending activation system of the brainstem reticular structure, the function of the pyramidal system, improves motor paralysis, and has a certain effect on promoting the recovery of brain function and awakening. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ganciclovir |
Nucleoside antiviral drugs. After entering the cell, this product is rapidly phosphorylated to a monophosphate compound, and then becomes a triphosphate compound through the action of cellular kinase. Its phosphorylation in cells infected with cytomegalovirus is faster than that in normal cells. Ganciclovir can competitively inhibit DNA polymerase and incorporate into the DNA of viruses and host cells, thereby inhibiting DNA synthesis. This product has a stronger inhibitory effect on viral DNA polymerase than host cell polymerase. In animal experiments, this product has teratogenic, carcinogenic, immunosuppressive effects and reproductive system toxicity.
More
Nucleoside antiviral drugs. After entering the cell, this product is rapidly phosphorylated to a monophosphate compound, and then becomes a triphosphate compound through the action of cellular kinase. Its phosphorylation in cells infected with cytomegalovirus is faster than that in normal cells. Ganciclovir can competitively inhibit DNA polymerase and incorporate into the DNA of viruses and host cells, thereby inhibiting DNA synthesis. This product has a stronger inhibitory effect on viral DNA polymerase than host cell polymerase. In animal experiments, this product has teratogenic, carcinogenic, immunosuppressive effects and reproductive system toxicity. |
82410-32-0 | 36 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ganciclovir |
Nucleoside antiviral drugs. After entering the cell, this product is rapidly phosphorylated to a monophosphate compound, and then becomes a triphosphate compound through the action of cellular kinase. Its phosphorylation in cells infected with cytomegalovirus is faster than that in normal cells. Ganciclovir can competitively inhibit DNA polymerase and incorporate into the DNA of viruses and host cells, thereby inhibiting DNA synthesis. This product has a stronger inhibitory effect on viral DNA polymerase than host cell polymerase. In animal experiments, this product has teratogenic, carcinogenic, immunosuppressive effects and reproductive system toxicity.
More
Nucleoside antiviral drugs. After entering the cell, this product is rapidly phosphorylated to a monophosphate compound, and then becomes a triphosphate compound through the action of cellular kinase. Its phosphorylation in cells infected with cytomegalovirus is faster than that in normal cells. Ganciclovir can competitively inhibit DNA polymerase and incorporate into the DNA of viruses and host cells, thereby inhibiting DNA synthesis. This product has a stronger inhibitory effect on viral DNA polymerase than host cell polymerase. In animal experiments, this product has teratogenic, carcinogenic, immunosuppressive effects and reproductive system toxicity. |
82410-32-0 | 36 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Amikacin sulfate salt |
Aminoglycoside antibiotics have antibacterial effects on most Enterobacteriaceae, Pseudomonas aeruginosa, some other Pseudomonas, Acinetobacter, Alcaligenes, meningococci, gonococci, influenza bacilli, Yersinia, Campylobacter fetus, Mycobacterium tuberculosis and some Mycobacterium. Its mechanism of action is to act on the 30S subunit of bacterial ribosomes and inhibit bacterial protein synthesis. Combination with semi-synthetic penicillins or cephalosporins often produces synergistic antibacterial effects.
More
Aminoglycoside antibiotics have antibacterial effects on most Enterobacteriaceae, Pseudomonas aeruginosa, some other Pseudomonas, Acinetobacter, Alcaligenes, meningococci, gonococci, influenza bacilli, Yersinia, Campylobacter fetus, Mycobacterium tuberculosis and some Mycobacterium. Its mechanism of action is to act on the 30S subunit of bacterial ribosomes and inhibit bacterial protein synthesis. Combination with semi-synthetic penicillins or cephalosporins often produces synergistic antibacterial effects. |
149022-22-0 | 9 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Amikacin sulfate salt |
Amikacin sulfate is an aminoglycoside antibiotic that has antibacterial effects on most Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter, Alcaligenes, meningococci, gonococci, influenza bacilli, Yersinia, Campylobacter fetus, Mycobacterium tuberculosis and some Mycobacterium. Its antibacterial activity is slightly lower than that of gentamicin, but it is stable to the aminoglycoside inactivating enzymes produced by many intestinal Gram-negative bacilli and will not lose its antibacterial activity due to inactivation of such enzymes. The mechanism of action is to act on the 30S subunit of the bacterial ribosome and inhibit bacterial protein synthesis. Combination with semi-synthetic penicillins or cephalosporins often achieves a synergistic antibacterial effect.
More
Amikacin sulfate is an aminoglycoside antibiotic that has antibacterial effects on most Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter, Alcaligenes, meningococci, gonococci, influenza bacilli, Yersinia, Campylobacter fetus, Mycobacterium tuberculosis and some Mycobacterium. Its antibacterial activity is slightly lower than that of gentamicin, but it is stable to the aminoglycoside inactivating enzymes produced by many intestinal Gram-negative bacilli and will not lose its antibacterial activity due to inactivation of such enzymes. The mechanism of action is to act on the 30S subunit of the bacterial ribosome and inhibit bacterial protein synthesis. Combination with semi-synthetic penicillins or cephalosporins often achieves a synergistic antibacterial effect. |
149022-22-0 | 9 |